Keywords: USA, Biotechnology stocks, IPOs, Burrill, Dendreon, Amgen, Gilead

Biotech posts weak performance in April, reflecting toll of US health care reform

Article | 18 May 2010

Print This

Despite the pop in the shares of Dendreon on the announcement that its prostate cancer therapy Provenge (sipuleucel-T) had finally ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in